Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Antibe Therapeutics's share price for the quarter that ended in Dec. 2023 was C$0.93. Antibe Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 52.67 Mil. Therefore, Antibe Therapeutics's market cap for the quarter that ended in Dec. 2023 was C$48.98 Mil.
Antibe Therapeutics's quarterly market cap
increased
from Jun. 2023 (C$24.21 Mil) to Sep. 2023 (C$25.79 Mil) and
increased
from Sep. 2023 (C$25.79 Mil) to Dec. 2023 (C$48.98 Mil).
Antibe Therapeutics's annual market cap
declined
from Mar. 2021 (C$232.73 Mil) to Mar. 2022 (C$41.16 Mil) and
declined
from Mar. 2022 (C$41.16 Mil) to Mar. 2023 (C$31.57 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Antibe Therapeutics's Enterprise Value for Today is C$-39.17 Mil.
Antibe Therapeutics Market Cap Historical Data
The historical data trend for Antibe Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Antibe Therapeutics's Market Cap
For the Biotechnology subindustry, Antibe Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Antibe Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Antibe Therapeutics's Market Cap falls into.
Antibe Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Antibe Therapeutics's Market Cap for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antibe Therapeutics (TSX:ATE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Antibe Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Antibe Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Antibe Therapeutics (TSX:ATE) Business Description
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSX:ATE has been successfully added to your 